Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 451 to 500 of 2013

TitleReference numberPublishedLast updated
Eptinezumab for preventing migraineTA871
Cannabidiol for treating seizures caused by tuberous sclerosis complexTA873
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphomaTA874
Endoluminal gastroplication for gastro-oesophageal reflux diseaseHTG661
Percutaneous transluminal renal sympathetic denervation for resistant hypertensionHTG662
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapiesTA872
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin geneHST22
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myelomaTA870
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)TA867
Vutrisiran for treating hereditary transthyretin-related amyloidosisTA868
Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and managementNG231
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinomaTA865
Regorafenib for previously treated metastatic colorectal cancerTA866
Transvenous obliteration for gastric varicesHTG658
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancerHTG659
Upadacitinib for treating active non-radiographic axial spondyloarthritisTA861
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatmentsTA862
Somatrogon for treating growth disturbance in children and young people aged 3 years and overTA863
Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predictedTA864
Delirium: prevention, diagnosis and management in hospital and long-term careCG103
Maribavir for treating refractory cytomegalovirus infection after transplantTA860
Trabeculectomy with a biodegradable collagen matrix implant for glaucomaHTG656
Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)TA859
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and educationNG213
MRI-based technologies for assessing non-alcoholic fatty liver diseaseHTG655
Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinomaTA857
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinomaTA858
Transcutaneous electrical stimulation of the trigeminal nerve for ADHDHTG653
Laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux diseaseHTG654
Hip fracture: managementCG124
Upadacitinib for treating moderately to severely active ulcerative colitisTA856
Percutaneous image-guided cryoablation of peripheral neuroma for chronic painHTG652
Thyroid cancer: assessment and managementNG230
Avatrombopag for treating primary chronic immune thrombocytopeniaTA853
Cabozantinib for previously treated advanced hepatocellular carcinomaTA849
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapyTA850
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancerTA851
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatmentsTA852
Esketamine nasal spray for treatment-resistant depressionTA854
Memokath 051 Ureter stent for ureteric obstructionHTG651
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)TA848
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal)TA845
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal)TA846
Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal)TA847
Optilume for treating recurrent bulbar urethral stricturesHTG649
GreenLight XPS for treating benign prostatic hyperplasiaHTG650
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal)TA843
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal)TA844
Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and managementNG228
Fractures (complex): assessment and managementNG37

Results per page

  1. 10
  2. 25
  3. 50
  4. All